Chinas domestic crown disease oral medication pills first Nuoxins producti

China ’s domestic oral medication medicine has been listed on the market, and current production capacity is climbing.

According to the surging news report, Sunday (February 26), Sunday (February 26), held a list of domestic crown disease oral medicines.Xian Nuoxin was the first domestic 3CL crown disease oral medicine. It was specially approved by the State Drug Administration on January 28 and was listed in China.The drug was officially launched on February 11, and it was successively supplied to various medical institutions.

Introduction to Xianmin Pharmaceuticals, the current production capacity of Xianninxin is climbing. In order to ensure that patients with diagnosis are used in time, the company has invested in special resources and accelerated hospital access.

Public information shows that Xian Nuoxin packaged the combined packaging of Xiannutwe and Litonovir tablets.The use of low -dose Litonovo can help slow down the metabolism or decomposition of the first Nortow in the body and improve the effect of antiviral effects.

How long does it take for the production of Xian Nuoxin? Introduction to the pioneering pharmaceutical industry, the production process of the drug is more complicated.And complicated preparation processes such as hot melting extrusion.Relevant person in charge said that it takes more than 50 days from the drug drug to the preparation.

At present, the main production base of Xian Nuoxin is the Hainan Factory and the Nanjing Factory of Xianyou Pharmaceuticals. Xianyou Pharmaceuticals said that the production line may be adjusted according to the changes in the epidemic in the future.At present, Nuoxin's production capacity is climbing.In order to ensure that patients with diagnosis are used as soon as possible, especially to ensure the timely medication of fragile people, the company has put into special resources, builds a "guarantee network" and accelerates hospital access.

3CL protease and RDRP are the two main targets of global anti -coronary drugs. Among the five crown disease oral medicines that have been approved in China, the targets of Xian Nuoxin and Phaxlovid are both3CL.